ArriVent BioPharma (AVBP) Restructuring Costs (2024 - 2026)

ArriVent BioPharma has disclosed Restructuring Costs across 3 years of filings, most recently posting $2.3 million for Q1 2026.

• Restructuring Costs for Q1 2026 came in at $2.3 million, up 7.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (up 17.2% YoY), and the FY2025 annual result was $8.8 million, up 22.77% from the prior year.
• Restructuring Costs came in at $2.3 million for Q1 2026 at ArriVent BioPharma, up from $2.3 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $2.4 million in Q2 2025 to a low of $1.5 million in Q4 2024.
• The 3-year median for Restructuring Costs is $2.1 million (2024), against an average of $2.0 million.
• Peak annual rise in Restructuring Costs reached 54.86% in 2025, while the deepest fall reached 7.37% in 2025.
• ArriVent BioPharma's Restructuring Costs stood at $1.5 million in 2024, then soared by 54.86% to $2.3 million in 2025, then grew by 2.21% to $2.3 million in 2026.
• The last three Restructuring Costs figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.